Iridex Announces First Patient Enrolled in an Independent Landmark Investigator-Led UK Study Evaluating MicroPulse® Technology as an Adjunct to anti-VEGF Therapy for Diabetic Macular Edema

Stock Information for IRIDEX Corporation

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About IRIDEX Corporation

Iridex Reports Third Quarter 2025 Financial Results
Iridex to Report Third Quarter 2025 Financial Results on November 11, 2025
Iridex Corporation Receives Formal Notification of Nasdaq Listing Compliance
Iridex Reports Second Quarter 2025 Financial Results
Iridex to Report Second Quarter 2025 Financial Results on August 12, 2025
Iridex Reports First Quarter 2025 Financial Results
Iridex to Report First Quarter 2025 Financial Results on May 13, 2025
Iridex Announces Preliminary Operational and Financial Results for the First Quarter 2025

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.